SARS coronavirus-2 vaccines: options and state-of-the-art

Anke L W Huckriede*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

2007 Downloads (Pure)

Abstract

Since the first reports in mid-January of a serious new viral respiratory infection, COVID-19, and the identification of SARS-CoV-2 as the cause of this disease, researchers work intensely on developing a vaccine that can protect individuals against serious disease and that can limit the spread of the virus. Vaccine developers are using a range of platform technologies to do this, each with advantages and disadvantages. Close to 30 vaccines are now in clinical testing. The first results are encouraging, but in order to properly assess the merits of the different vaccines, we must wait for the results of phase 3 trials. The first phase 3 trials have started in July 2020.

Translated title of the contributionSARS coronavirus-2 vaccines: options and state-of-the-art
Original languageDutch
Article numberD5352
Number of pages7
JournalNederlands Tijdschrift voor Geneeskunde
Volume164
Issue number37
Publication statusPublished - 3-Sep-2020

Cite this